| Here's Why You Should Consider Moderna Stock, and No, It's Not the COVID Vaccine 5:30am / MotleyFool.com - Paid Partner Content | Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study Sep 22 / Zacks.com - Paid Partner Content |
| Merck (MRK) Dips More Than Broader Markets: What You Should Know Sep 29 / Zacks.com - Paid Partner Content | Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications Sep 22 / Zacks.com - Paid Partner Content |
| Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs Sep 29 / Zacks.com - Paid Partner Content | 3 Reasons to Buy Merck Stock Sep 22 / MotleyFool.com - Paid Partner Content |
| Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244% Sep 29 / Zacks.com - Paid Partner Content | Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar? Sep 22 / Zacks.com - Paid Partner Content |
| Ligand (LGND) Acquires Certain Assets of Novan for $12.2M Sep 28 / Zacks.com - Paid Partner Content | Merck (MRK) Stock Moves -0.54%: What You Should Know Sep 21 / Zacks.com - Paid Partner Content |
| The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy Sep 28 / Zacks.com - Paid Partner Content | Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag Sep 21 / Zacks.com - Paid Partner Content |
| Merck (MRK) Stock Sinks As Market Gains: What You Should Know Sep 27 / Zacks.com - Paid Partner Content | Merck (MRK) Stock Moves -0.05%: What You Should Know Sep 20 / Zacks.com - Paid Partner Content |
| Top Stock Reports for Alphabet, Exxon Mobil & Merck Sep 27 / Zacks.com - Paid Partner Content | FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma Sep 20 / Zacks.com - Paid Partner Content |
| Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies Sep 25 / Zacks.com - Paid Partner Content | Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View Sep 19 / Zacks.com - Paid Partner Content |
| Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study Sep 25 / Zacks.com - Paid Partner Content | Why Shares of Iovance Biotherapeutics Jumped Monday Sep 18 / MotleyFool.com - Paid Partner Content |
| The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca Sep 25 / Zacks.com - Paid Partner Content | Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer Sep 18 / Zacks.com - Paid Partner Content |
-1.30 / -1.25%